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Abstract 
Background 
At the end of 2011, a new orthobunyavirus, tentatively named Schmallenberg virus (SBV), 
was discovered in Germany. This virus has since been associated with clinical signs of 
decreased milk production, watery diarrhoea and fever in dairy cows, and subsequently also 
with congenital malformations in calves, lambs and goat kids. In affected countries, initial 
surveillance for the infection was based on examination of malformed progeny. These 
suspicions were followed up by real-time reverse transcription polymerase chain reaction 
(RT-PCR) on brain tissue. For epidemiological purposes, a serological assay was, however, 
needed. 
Results 
A virus neutralisation test (VNT) was developed and optimized, and subsequently evaluated. 
This VNT has a specificity of >99 % and the sensitivity is likely also very close to 100 %. 
The assay is highly repeatable and reproducible. The final assay was used to test for 
antibodies in cows, ewes and does from herds known to be infected or suspected to be so. 
Targets for sampling in these herds were the mothers of malformed offspring. In herds with 
an RT-PCR confirmed SBV infection, more than 94 % (190 out of 201) of the ewes and 99 % 
(145 out of 146) of the cows were seropositive. In herds with suspicion of SBV infection 
based on birth of malformed offspring only (no or negative RT-PCR), more than 90 % (231 
out of 255) of the ewes and 95 % (795 out of 834) of the cows were seropositive. In goats, on 
the other hand, only a low number of seropositives was found: overall 36.4 %, being 16 out 
of 44 goats tested. 
Conclusions 
Given the characteristics of this VNT, it can be used at a relative high throughput for testing 
of animals for export, surveillance, screening and research purposes, but can also be used as a 
confirmation test for commercially available enzyme-linked immunosorbent assays 
(ELISA’s) and for (relative) quantification of antibodies. 
Suspicions of SBV infections that were confirmed by RT-PCR were almost always confirmed 
by serology in cows. Due to individual registration and identification of cows and calves, 
affected offspring could almost always be traced back to the mother. Ewes on the other hand 
were not always the mothers of affected lambs, but were in many cases herd mates with 
unaffected lambs. This indicated a high within-herd seroprevalence of antibodies against 
SBV. 
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Background 
On the 18
th
 of November 2011, the finding of a new orthobunyavirus was reported by the 
Friedrich Loeffler Institute (FLI) in Germany [1]. This virus is closely related to 
Shamondavirus, which belongs to the Simbu serogroup of the genus Orthobunyavirus, family 
Bunyaviridae [2]. The virus, provisionally called Schmallenberg virus (SBV), has since been 
associated with clinical signs of decreased milk production, watery diarrhoea and fever that 
had occurred in the months of August and September in dairy cows in the Netherlands [3] 
and Germany [1]. In Germany, twelve samples from six affected herds that were tested with a 
real-time reverse transcription polymerase chain reaction test (RT-PCR) were positive for 
viral RNA of SBV [1]. In the Netherlands, using the same RT-PCR, viral RNA of SBV was 
detected in 36 % of stored blood samples from herds that had reported clinical signs earlier. 
In contrast, none of the samples from herds without clinical signs in the Netherlands were 
RT-PCR positive for SBV [3]. 
Subsequently, SBV infections were also associated with congenital arthrogryposis and 
hydranencephaly syndrome in newborn lambs [4]. A first malformed goat kid was reported 
PCR-positive for SBV on 3 January 2012 in the Netherlands [5] and the first malformed calf 
was reported PCR-positive for SBV on 7 January 2012 in Germany [6]. 
To determine the seroprevalence and carry out epidemiological studies, the immediate need 
arose for a reliable and robust serological assay. To address this need, a virus neutralisation 
test (VNT) was developed, as this also allows for a semiquantitative detection of antibodies 
against the virus. Furthermore, a protocol was established that allows for a relatively high 
throughput. Even though in April 2012 a first commercial enzyme-linked immunosorbent 
assay (ELISA) became available, a VNT remains a possible alternative as a screening test, 
but is also useful as a confirmation test or a semiquantitative test to be used in experimental 
infections, when amounts of antibodies need to be determined. The development of the VNT 
is described, evaluating the diagnostic specificity and sensitivity, repeatability and 
reproducibility, and robustness, and use of the test on RT-PCR positive herds and herds 
suspected to be infected, i.e. occurrence of malformed progeny, with negative RT-PCR 
results or RT-PCR not performed. 
Methods 
Medium 
The medium used was DMEM + Glutamax (Gibcom, Bleiswijk, the Netherlands) with 3 % 
foetal calf serum (FCS), penicillin (100 units/ml), and streptomycin (100 μg/ml). FCS was 
inactivated for 30 min at 56 °C. This medium was used in all cell cultures and to dilute serum 
samples and virus stock. 
Cell culture 
Vero cells were used to grow the virus and also in the VNT. They were grown in 600 ml (150 
cm
2
) cell culture flasks (Becton Dickinson, Breda, the Netherlands). Depending on the need 
for cells and availability of cells, flasks were seeded with 6 to 10 million cells, with 50 ml of 
medium, and incubated at 37 °C, in an atmosphere of 5 % CO2. Cells for the VNT were 
counted with a cell counter (Beckman Coulter, Woerden, the Netherlands) and diluted to a 
concentration of 2x10
5
 cells/ml. 
Virus 
The virus for the VNT was isolated from the brain of a new-born lamb with malformations 
that had tested positive in the SBV RT-PCR. A virus stock containing approximately 10
5
 
median tissue culture infective dose (TCID50) per ml (3
rd
 passage) was grown initially on 
Vero cells and used to develop and optimize the VNT. A second, larger batch of virus, with a 
titre of approximately 10
6.7
 TCID50/ml (4
th
 passage) was grown also on Vero cells and used 
for the initial validation of the final test protocol and subsequent routine diagnostic tests. 
Titres were determined by amido black staining, similar to back titration of the virus in the 
VNT (see paragraph “Back titration of virus”). 
Development of the VNT 
Several variables were changed and tested during the development of the assay to determine 
the optimal conditions, but also the robustness of the VNT: 
• Number of cells per well: 5000, 10,000, 20,000, and 50,000. 
• Age of cells (time to harvesting after incubation): 3 to 16 days. 
• Percentage of FCS in medium: 1 %, 3 %, and 5 %. 
• Neutralisation time: 1, 2, and 4 hours. 
• Incubation period: 3, 4, and 5 days. 
• Amount of virus: 100 and 500 TCID50. 
• Two different batches of FCS. 
• Microscopic reading of the plates without staining (cytopathic effect [CPE]) vs. 
macroscopic reading of the plates after amido black staining. 
Final VNT protocol 
The VNT was carried out in flat bottomed 96 well micro titre plates. In each well of the first 
column, 75 μl of medium was pipetted, in all other wells 50 μl of medium. Serum samples 
were inactivated for 30 min at 56 °C and 25 μl was subsequently added to a well in the first 
column to obtain a starting dilution of 1:4. From this well, two-fold dilutions were made by 
pipetting 50 μl of each well in the next, until the last column. From the final column, 50 μl 
was discarded, so that each well now contained 50 μl of the diluted sample. 
Subsequently, virus (500 TCID50 per well) was added to each well, also in a volume of 50 μl. 
Serum and virus were pre-incubated at 37 °C for 1 to 2 hours to allow neutralisation of the 
virus. Thereafter, 20,000 cells per well were added in a volume of 100 μl. Plates were then 
incubated for 5 days at 37 °C and under 5 % CO2. 
After 5 days, the plates were emptied, washed once with 0.15 M NaCl and then stained with 
amido black (0.1 % amido black solution (w/w) with 5.4 % acetic acid, 0.7 % sodium acetate 
and 10 % glycerol) for 30 min. Washing fluids were caught in a container with disinfectant, 
to inactivate the virus. Subsequently, plates were rinsed with tap water and read 
macroscopically. Wells with 25-100 % staining were considered to have no or limited CPE 
only. Wells with less than 25 % staining were considered to have extensive or full CPE. In 
each dilution series the last well with no or limited CPE (25-100 % staining) was identified 
and the sample was assigned a titre that was the reciprocal of the dilution in that well. 
Control samples 
Control samples included serum samples from 2 seronegative sheep, 4 seropositive sheep and 
2 seropositive dairy cows. The positive samples were obtained from sheep and dairy cows 
from herds in which congenital malformations were seen and confirmed by RT-PCR. The 
samples had tested consistently positive in subsequent prototypes of the VNT. These control 
samples were included in each run of the test and were also used to optimize the assay. 
Back titration of virus 
Virus used in each run of the test was back titrated in 4 tenfold dilutions. If a working stock 
of 100 TCID50/well was used in the test, 10
0
, 10
-1
, 10
-2
, and 10
-3
 dilutions of that working 
stock were used in the back titration. If a working stock of 500 TCID50/well was used in the 
test, 10
-1
, 10
-2
, 10
-3
 and 10
-4
 dilutions of that working stock were used in the back titration. 
Each dilution was tested in 12 or 24 wells during the development phase and routine 
diagnostic phase respectively. The virus titre was determined with the Reed-Münch method 
[7]. 
Diagnostic specificity and sensitivity 
To determine the optimal cut-off of the assay, with a high diagnostic specificity and 
sensitivity, 348 blood samples from non-infected animals were tested in the final version of 
the assay. These samples originated from the Netherlands from the period of 2000–2010, 
supposedly before the introduction of SBV. From sheep 156 samples were available and 192 
from cattle. They were used to set the cut-off value in the assay and estimate the specificity. 
Subsequently, 366 field samples were tested that originated from herds in which congenital 
malformations were observed to get a first indication of the sensitivity of the test. 
Repeatability and reproducibility 
To test for repeatability of the assay, 646 samples from suspect and infected herds were tested 
in duplicate, in 8 dilutions. The number of mismatches between duplicates was tabulated to 
get a first indication of the repeatability. For reproducibility, the results from the control 
panel of 4 runs were used. For each sample the standard deviation of the log-transformed 
titres was calculated. The standard deviations of all 8 samples were averaged, to get a first 
indication of the reproducibility. 
Field study 
From the end of February 2012 both an RT-PCR and the VNT were used as routine 
diagnostic tests to confirm or rule out SBV infections in case of congenital malformation. 
The samples used in this study were collected in the field from the end of December 2011 
until the 14
th
 of May 2012. Common procedure was that malformed calves, lambs and goat 
kids would be submitted for a post-mortem. If an infection with SBV was suspected, based 
on arthrogryposis and hydranencephaly, a brain sample was tested in by RT-PCR for SBV, 
while the competent authorities would trace the mother of the affected offspring to take a 
blood sample for serological testing. However, tracing of the mother was not always possible, 
especially in sheep due to lack of individual registration of mothers and lambs at that age. 
Therefore, in many cases a ewe that was not the mother of the malformed lamb would be 
sampled from the herd instead. Until mid-May, a total number of 1480 blood samples were 
tested in the VNT, originating from 1205 different herds (30 goat, 259 sheep and 916 cattle 
herds). These herds were divided in two categories: 
– Suspect herds, being herds with occurrence of malformed progeny, but either no or only 
negative RT-PCR results. 
– Infected herds, being herds with occurrence of malformed progeny, and a positive RT-
PCR result. 
All samples were tested in the final VNT-protocol that was evaluated as described above. 
Results 
Development of the assay and robustness 
Several variables were tested and evaluated while developing and optimizing the assay. 
Percentage of FCS (from 1-5 %), neutralisation time (1–4 hours), age of cells (3 to 16 days), 
and different batches of FCS gave the same result and were not crucial within the tested 
range. The percentage of FCS was therefore fixed at 3 %, with a neutralisation time of 1–2 
hours for the final protocol. The test is, however, robust for these variables, within given 
ranges. 
The number of cells, on the other hand, was crucial. A total of 20,000 cells per well gave 
confluent monolayers and full staining of non-affected cells, while 5,000 or 10,000 cells per 
well gave rather thin and sometimes incomplete monolayers. Especially for easiness of 
reading, 20,000 cells per well was included in the final protocol, as 50,000 cells per well gave 
no further improvement. 
Microscopic reading of the plates turned out to be laborious and quite difficult to standardize 
between observers who were reading the test. Given the need for a relatively high throughput 
VNT, this was abandoned in favour of amido black staining and macroscopic reading of the 
plates. Even though CPE was defined as 75 % of the monolayer gone, which seems a 
somewhat subjective criterion, this was very easy to standardize between observers and rarely 
resulted in discrepancies. 
For the amido black staining, crucial differences were noticed when using different virus 
concentrations and incubation periods. These results are shown in Table 1 and Figure 1, 
where test plates were prepared in triplicate, of which one plate was stained and read after 3, 
4 and 5 days respectively. In Table 1 it is shown that back titration of the virus yields higher 
titres when plates are read microscopically and that higher titres are observed after longer 
incubation periods. Serum titres are higher when using 100 TCID50 instead of 500 TCID50 (as 
can be expected), and serum titres are decreasing after longer incubation periods, as more 
CPE develops. In Figure 1 it is clearly shown that incubation for a longer period results in 
plates that are easier to read. Especially after 5 days, and with 500 TCID50, there is a good 
contrast between wells with and without CPE. This is even more so the case for the back 
titration of the virus. An incubation period of 5 days and 500 TCID50 were therefore included 
in the final protocol. 
Table 1 Back titrations (in TCID50/well) and average titres of positive (n = 6) and 
negative (n = 2) samples, depending on intended TCID50 per well (100 vs. 500) and days 
of incubation of the VNT (3, 4, or 5 days). Plates were read in two ways: microscopic 
(Microsc), where CPE was defined as even a single plaque of CPE, and with amido black 
staining (AmidoB), where CPE was defined as 75 % or more of the monolayer gone (is <25 
% staining) 
 100 TCID50 500 TCID50 
3 days 4 days 5 days 3 days 4 days 5 days 
Virus titres 
Back titration Microsc 59 154 202 314 720 1389 
AmidoB 7 41 56 35 187 562 
Antibody titres 
Positive samples Microsc 211 215 181 78 57 51 
AmidoB 2048 813 287 575 228 181 
Negative samples Microsc 3 4 3 3 2 3 
AmidoB 16 6 3 6 4 3 
Figure 1 Amido black staining of control plates, for comparison of 100 vs. 500 TCID50 
and 3, 4 and 5 days of incubation. A: Back titrations of both virus concentrations, shown in 
the upper 3 plates, were carried out on one plate per incubation period, in 4 tenfold dilutions 
starting from 10
0
 (100 TCID50, upper 4 rows) or 10
-1
 (500 TCID50, lower 4 rows). B: Results 
of the control panel of 6 positive (P) and 2 negative (N) samples, are shown in the middle 
row of 3 plates (100 TCID50) and the lower row of 3 plates (500 TCID50). Serum dilutions are 
shown above the figures. Results of back titration and average titres are given in Table 1 
Diagnostic specificity of the VNT 
In serum samples from non-infected sheep, a higher background was seen than in sera from 
non-infected cattle (Figure 2). Based on testing 156 sheep and 192 cows, the cut-off values 
were set at a titre of 16 for sheep and 8 for cattle. Given this cut-off value, a specificity of 
99.4 % (95 % CI: 96.6-99.9 %) in sheep and 99.5 % (95 % CI: 97.1-99.9 %) in cattle was 
estimated (Figure 2). No negative samples from goats were available, and the cut-off value 
was set to 16, similar to sheep. 
Figure 2 Distribution of titres in non-infected sheep (n = 156) and cattle (n = 192) (bars, 
left axis). Serum samples were tested in two fold dilutions from 1:4 until 1:128. Specificity 
of the VNT in sheep and cattle serum samples, depending on cut-off value (a cut-off value of 
4 meaning that all titres of 4 and above are considered positive, etc.) for sheep and cattle is 
shown with the lines (right axis) 
Diagnostic sensitivity of the VNT 
Due to the lack of well-defined serum samples, no real estimate of the diagnostic sensitivity 
was initially possible. From the 366 field samples that were tested during the evaluation of 
the final test protocol, 92 % of the cattle and 94 % of the sheep scored positive in the VNT. In 
sheep no titres of 8 and in cattle no titres of 4 were observed, thus clearly separating the peak 
of the positive samples from the peak of the negative samples (Figure 3). This supports the 
cut-off value of 16 and 8 respectively for sheep and cattle, as determined already by testing 
serum samples from non-infected animals. Assuming the worst case scenario, that all were 
seropositive in reality, sensitivity of the assay would therefore be at least 92 % and 94 % in 
cattle and sheep respectively. However, the clear separation of the negative and positive peak 
suggests that the sensitivity for both species is close to 100 %. In goats only 8 samples were 
positive, out of 36 samples tested. 
Figure 3 Distribution of titres in goats, sheep and cattle in a total of 366 samples from 
herds with congenital malformations 
Repeatability and reproducibility 
From 646 samples tested in duplicate, 398 (61.6 %) were identical. In 235 samples (36.4 %) 
there was one dilution step difference between the duplicates and in 11 samples (1.7 %) the 
difference was two dilution steps. In two samples (0.3 %) the difference was 5 and 6 dilution 
steps respectively, and these were the only 2 samples in which the qualitative result 
(positive/negative) would be different if the result was to be based on either of the duplicates. 
Based on qualitative results, the repeatability was therefore 99.7 %. 
The average standard deviation of the control samples in 4 different test runs was 0.52 log2, 
which is slightly more than half a dilution step. Titres were therefore reproducible on average 
with a range of plus or minus half a dilution step. 
Field study 
In cattle, 135 out of 916 herds with occurrence of malformations (14.7 %) were confirmed 
infected with SBV by RT-PCR. In infected herds, 99.3 % of the cows tested positive in the 
VNT, while 95.3 % were seropositive in suspect herds (Table 2). 
Table 2 Result of a serological field study in cattle, sheep and goat herds, carried out 
with the VNT. Suspect herds being herds with occurrence of malformed offspring, but either 
negative SBV RT-PCR results on a herd level, or no RT-PCR results. Infected herds being 
herds with occurrence of malformed offspring and a positive SBV RT-PCR result 
 Herds Blood samples 
Tested PCR+ PCR- No PCR test Tested Positive (%) 
Cattle Total 916 135 751 30 980 940 (95.9 %) 
Suspect 781 - 751 30 834 795 (95.3 %) 
Infected 135 135 - - 146 145 (99.3 %) 
Sheep Total 259 79 168 12 456 421 (92.3 %) 
Suspect 180 - 168 12 255 231 (90.6 %) 
Infected 79 79 - - 201 190 (94.5 %) 
Goats Total 30 3 22 5 44 16 (36.4 %) 
Suspect 27 - 22 5 35 14 (40.0 %) 
Infected 3 3 - - 3 2 (66.7 %) 
In sheep, 79 out of 259 herds with occurrence of malformations (30.5 %) were confirmed 
infected with SBV by RT-PCR. In infected herds, 94.5 % of the ewes tested positive in the 
VNT, while 90.6 % were seropositive in suspect herds. 
In goats, fewer cases of malformations were reported and investigated, and in 3 out of 30 
herds (10 %) SBV was confirmed by RT-PCR. Two out of three does tested in these infected 
herds were positive in the VNT. In suspect herds, 40 % of the does tested positive in the 
VNT. 
Discussion 
A very robust VNT was developed with a very high specificity and sensitivity, both close to 
100 %, in sheep and cattle. The assay was shown to be highly repeatable and reproducible. 
The VNT is easy to perform and can be read macroscopically as a result of the amido black 
staining. With the current, optimized protocol, this staining results most of the times in a very 
sharp transition between wells with and without CPE. This makes it easy and very fast to read 
the plates, with a high reliability and reproducibility. A serum control for each individual 
sample was not included during our evaluation of the test. No evidence for a toxic effect of 
serum on the cells was ever noticed, but to avoid false negative results, routine use of a serum 
control could be considered. 
In infected herds, i.e. confirmed by RT-PCR, more than 94 % of the sheep and 99 % of the 
cows tested seropositive. The ewes and cows tested were sampled because of congenitally 
malformed offspring. In lambs, approximately 30 % of these malformations were confirmed 
to be positive for SBV by RT-PCR on brain tissue. However, in many cases it was not 
possible to trace the confirmed SBV-positive lambs back to the exact mother, so the serum 
blood sample was sometimes obtained from other ewes in the herd. Nevertheless, more than 
94 % of these ewes tested seropositive, suggesting that at least within these sheep herds with 
congenital malformations, the infection is widespread with a high within-herd 
seroprevalence. 
Calves with malformations, on the other hand, could usually be traced back to the mother and 
from these cows serum blood samples were collected for serology. More than 99.3 % of these 
mothers were seropositive. These cattle sera originated from cows that gave birth to 
malformed calves that were positive in the RT-PCR for SBV and are currently the most well-
defined serum samples from previously infected animals. The sensitivity of the VNT can be 
estimated most reliably from these samples and is therefore >99 %, which is in line with the 
estimation during the initial evaluation of the test, based on the distribution of titres in a 
smaller set of field samples. 
In suspect herds, SBV was not confirmed by RT-PCR and in some cases RT-PCR was not 
carried out at all. It is likely that the virus, after infecting the foetus and causing the 
malformations, was cleared during the last part of the gestation period, at least from the brain, 
which was the most common sampling site. The fact that calves were more often RT-PCR 
negative than lambs can then be explained by the longer gestation period in cows and 
supports this explanation. The fact that seroprevalences in suspect herds were slightly lower 
than in infected herds, suggests that also malformed offspring with defects unrelated to a 
SBV infection were submitted for testing. Given the high alertness for congenital 
malformations, this can be expected to happen. In any case it shows that serological assays 
are needed to reliably detect infections. 
High seroprevalences, both on a regional level, but also within herds, with and without 
obvious clinical signs, are not uncommon for viruses related to SBV. In Australia, 
seroprevalence studies into the related Akabane virus (AKAV), revealed within-herd 
seroprevalences of 77 % in 1964 [8], up to 89 % in 1971 [9] and 99 % in 1988 in the New 
South Wales area [10]. Furthermore, in Japan, 74 % of apparently healthy cattle cohabitated 
with cows showing clinical signs from an AKAV infection were seropositive also [11]. 
Finally, a very high seroprevalence is reported in the Netherlands, both within the 
Netherlands as a whole as in a few individual herds [12]. 
In goats the number of seropositive animals is far lower than in sheep and cattle, although 
less samples from goats were tested and the estimated seroprevalence is therefore less 
precise. Most of the malformations in goats therefore likely had another cause, as no infection 
with SBV could be proven in most of the mothers of the affected kids, neither by RT-PCR, 
nor by serology. Probably these affected kids were submitted and tested for SBV due to the 
ongoing outbreak and the high alertness for congenital malformations. These results may 
reflect a lower seroprevalence in goats in general. Given that goats, in contrast to cattle and 
sheep, are often housed indoors, and the SBV is supposedly transmitted by Culicoides 
vectors, like other viruses of the Simbu serogroup [2,13,14], this lower seroprevalence would 
not be surprising. 
Many countries outside the EU have closed their borders for cattle and sheep from SBV 
infected countries. Importing countries may require testing of animals originating from 
infected countries, which could include RT-PCR and/or serological testing. Although 
ELISA’s are being developed, and one became recently available on the market, the VNT 
that was developed, is a possible alternative. It is easy to carry out, and even though the 
incubation period is quite long with 5 days, hands-on time is relatively short. This means that 
the VNT is relatively cheap, and the total test capacity for an average laboratory to carry out 
the VNT could be quite high. Depending on the number of dilutions to be tested, whether 
samples will be tested in duplicate or not, and based on existing experience and logistics 
within a laboratory, thousands of samples could be tested per week. Costs of the VNT are 
mainly related to labour, while costs of an ELISA are for a large part expenditures on 
materials. Furthermore, the VNT could be used as a confirmation test and probably even a 
gold standard if further evaluated and validated. For (semi)quantitative studies, either in 
animal experiments or field studies, a VNT also has its advantages. 
Conclusion 
A very robust VNT was developed with a very high specificity and sensitivity, both close to 
100 %, in sheep and cattle. The assay was shown to be highly repeatable and reproducible. 
The VNT is easy to perform and can be read macroscopically as a result of the amido black 
staining. As such it can be used as a confirmation test for commercially available enzyme-
linked immunosorbent assays (ELISA’s) and for (relative) quantification of antibodies, but 
also at a relative high throughput for testing of animals for export, surveillance, screening and 
research purposes. 
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